Convalescent plasma therapy against the emerging SARS-CoV-2 variants: Delineation of the potentialities and risks
- 30 December 2021
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in International Journal of Surgery
- Vol. 97, 106204
- https://doi.org/10.1016/j.ijsu.2021.106204
Abstract
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in a catastrophic pandemic and severely impacted people's livelihoods worldwide. In addition, the emergence of SARS-CoV-2 variants has posed a severe threat to humankind. Due to the dearth of therapeutic options during the commencement of the pandemic, convalescent plasma therapy (CPT) played a significant part in the management of patients with severe form of COVID-19. Several recent studies have proposed various protective effects of CPT, such as antiviral, anti-inflammatory, anti-thrombotic, and immunomodulatory actions, curtailing the devastating consequences of the SARS-CoV-2 infection. On the contrary, several clinical studies have raised some serious concerns about the effectiveness and reliability of CPT in the management of patients with COVID-19. The protective effects of CPT in severely ill patients are yet to be proved. Moreover, the emergence of SARS-CoV-2 variants has raised concerns about the effectiveness of CPT against COVID-19. Therefore, to establish concrete evidence of the efficacy of CPT and adjudicate its inclusion in the management of COVID-19, an updated review of present literature is required, which could help in the development of an efficient therapeutic regimen to treat COVID-19 amid the emergence of new viral variants.Keywords
This publication has 91 references indexed in Scilit:
- Fighting Ebola with ZMapp: spotlight on plant-made antibodyScience China Life Sciences, 2014
- Reversion of advanced Ebola virus disease in nonhuman primates with ZMappNature, 2014
- A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing AntibodiesPLoS Pathogens, 2013
- Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus InfectionClinical Infectious Diseases, 2011
- Overview of the immune responseJournal of Allergy and Clinical Immunology, 2010
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- Use of convalescent plasma therapy in SARS patients in Hong KongEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirusClinical Microbiology & Infection, 2004
- Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patientsClinical Microbiology & Infection, 2004
- Treatment of West Nile Virus Encephalitis with Intravenous ImmunoglobulinEmerging Infectious Diseases, 2001